ABBOTT LABORATORIES_December 31, 2025

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 11-K

FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS

AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2025

☐

TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-2189

A.	Full title of the plan and the address of the plan, if different from that of the issuer named below:

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

B.	Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

ABBOTT LABORATORIES

100 Abbott Park Road

Abbott Park, Illinois 60064-6049

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ABBOTT LABORATORIES STOCK RETIREMENT PLAN

DECEMBER 31, 2025 AND 2024

C O N T E N T S

	Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	3

FINANCIAL STATEMENTS

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS	4

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS	5

NOTES TO FINANCIAL STATEMENTS	6

SUPPLEMENTAL SCHEDULE

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)	16

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (the “Plan”) as of December 31, 2025 and 2024, the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2025 and 2024, and the changes in net assets available for benefits for the year ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Supplemental information

The schedule of assets (held at end of year) as of December 31, 2025 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ GRANT THORNTON LLP

We have served as the Plan’s auditor since 2002.

Chicago, Illinois

June 18, 2026

Abbott Laboratories Stock Retirement Plan

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS

December 31, 2025 and 2024

(Dollars in thousands)


	2025		2024
Assets
Cash	$	—	$	1,011
Investments, at fair value		17,659,748		15,576,603
Employer contributions receivable		78,705		43,461
Notes receivable from participants		107,491		100,167
Accrued interest and dividend income		412		4,000
Due from brokers		642,109		30,426

Total assets		18,488,465		15,755,668

Liabilities
Investments sold short, at fair value		327,342		19,750
Cash overdraft		19,800		—
Accrued investment expenses		203		208
Due to brokers		300,104		10,441

Total liabilities		647,449		30,399

NET ASSETS AVAILABLE FOR BENEFITS	$	17,841,016	$	15,725,269

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

Year ended December 31, 2025

(Dollars in thousands)


Additions
Contributions
Employer	$	291,318
Participant		433,176
Rollovers		37,456

Total contributions		761,950

Investment income
Net appreciation in fair value of investments		2,619,788
Interest and dividends		138,283

Net investment income		2,758,071

Interest income on notes receivable from participants		7,184

Total additions		3,527,205

Deductions
Benefits paid to participants		1,411,233
Other expenses		225

Total deductions		1,411,458

NET INCREASE		2,115,747

Net assets available for benefits
Beginning of year		15,725,269

End of year	$	17,841,016

The accompanying notes are an integral part of this statement.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS

December 31, 2025 and 2024

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan is intended to constitute a profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, as amended (the “IRC”), with a cash or deferred arrangement under IRC Section 401(k), and a portion of the Plan is intended to constitute an employee stock ownership plan that meets the applicable requirements of IRC Sections 409 and 4975(e)(7). The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

In general, United States employees of Abbott Laboratories (“Abbott”) and selected participating subsidiaries and affiliates may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

Alight Solutions serves as the recordkeeper of the Plan. The Northern Trust Company (“Custodian” or “Trustee”) serves as the Plan’s custodian and trustee.

Contributions and Vesting

Contributions to the Plan are paid to the Abbott Laboratories Stock Retirement Trust (“Trust”). The Trust is administered by the Trustee and an investment committee (the “Committee”).

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate contribute from 2% up to 50% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from pretax earnings, after-tax earnings, or both. The Plan also permits Roth 401(k) contributions and has a Roth 401(k) conversion feature. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contributions are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options available under the Plan, except for investment options closed to new contributions.

Employer matching contributions to the Plan are made each payroll period based on the participating employee’s eligible earnings, unless the employee has elected to participate as a Freedom 2 Save Participant as described below. The employer matching contribution for the year ended December 31, 2025 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Participants may enroll in the Freedom 2 Save program in the Plan. A Freedom 2 Save participant who makes qualified student loan repayments of at least 2% of eligible earnings may receive a Freedom 2 Save employer contribution of 5% of eligible earnings shortly after the end of the year. An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will not receive employer matching contributions each payroll period but instead may receive a true-up employer matching contribution shortly after the end of the year for any payroll period for which the participant makes elective deferrals and does not receive a Freedom 2 Save employer contribution. Freedom 2 Save employer contributions and true-up employer matching contributions are only made on behalf of Freedom 2 Save participants who meet program guidelines, and who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or terminate employment due to death or qualifying disability during such Plan year.

Effective June 1, 2024, Plan participants who are not actively participating in the Abbott Laboratories Annuity Retirement Plan may receive an annual employer contribution equal to 3% of the participant’s eligible earnings, regardless of whether the participant contributes to the Plan. The 3% annual employer contribution will be made shortly after the end of the Plan year only to the eligible participants who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or who have terminated from employment during that Plan year due to death or qualifying retirement or disability during such Plan year.

Employer contributions are invested according to the participant’s investment elections.

Cash dividends on Abbott common shares are (1) paid in cash to the participants or beneficiaries, (2) paid to the Plan and distributed in cash to participants or beneficiaries no later than 90 days after the close of the Plan year for which paid, or (3) paid to the Plan and credited to the accounts in which shares are held, as elected by each participant or beneficiary in accordance with rules established by the administrator.

On January 1, 2013, Abbott separated into two publicly traded companies – Abbott and AbbVie Inc. (“AbbVie”). The separation of Abbott and AbbVie was a tax-free distribution where Abbott shareholders received one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Participants who received AbbVie stock through this distribution may continue to hold the stock in their Plan accounts but may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan; however, participants may elect to reinvest their AbbVie dividends in AbbVie stock. If no election is made, AbbVie dividends are invested in the Plan’s default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other available investment options.

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:


		Vesting
Service		percentage
Less than two years		0%
Two years or more		100%

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting – Continued

A participant becomes 100% vested in his or her employer contributions if, while employed by Abbott, he or she dies or attains age 65. Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in employer contributions upon qualifying disability.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

given period of time, (2) pay Plan expenses as deemed appropriate by the administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. Effective January 1, 2025, forfeitures are used to (1) restore any forfeitures of participants who returned to service with Abbott within a given period of time, and (2) reduce future employer contributions if terminated participants do not return to service within the given period of time.

In 2025, forfeitures reduced Abbott’s employer contributions by approximately $6.3 million. Approximately $1.0 million and $1.0 million in forfeitures were available at the end of 2025 and 2024, respectively.

Distributions and In-Service Withdrawals

Following retirement, termination or death (or for some participants from merged-in plans, upon disability), participants or their beneficiaries may elect to receive a distribution in installments, in a single lump sum or in a partial lump sum. Participants may elect a direct rollover of their accounts. Also, upon termination, participants may elect to defer distribution to a future date but, after termination of employment, distribution must be made by the 1^st of April following the year the participant reaches age 73 or, if earlier, the 31^st of December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including Roth rollover accounts and merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, subject to certain limitations.

Notes Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to IRC limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years. Repayment is made through periodic payroll deductions or by sending in payments, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Investment Valuation

The Plan offers a variety of investment options to participants. Certain investment options are structured as separately managed accounts; therefore, the Plan owns the individual investment holdings within the separately managed accounts and reflects them within the investments of the Plan.

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock, mutual funds, real estate investment trusts (“REITs”) and futures contracts - Valued at the published market price per share or unit multiplied by the number of respective shares or units held.

Collective trust funds and Private 40-Act mutual funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

Corporate debt and government debt - Valued at the published market price or prices obtained from independent financial services industry-recognized vendors multiplied by the number of respective units held. Prices obtained from vendors are on the basis of bid or mid evaluations in accordance to a region’s market convention, using factors which include but are not limited to market quotations, yields, maturities, and the bond’s terms and conditions. Proprietary methods are used to arrive at the evaluated price, which represent the price a dealer would pay for a security.

Futures contracts

One of the investment options structured as a separately managed account uses futures contracts as part of its investment strategy. A futures contract represents a commitment for the future purchase or sale of an asset or index at a specified price on a specified date. Futures contracts are exchange-traded and settle daily. Upon entering into the contracts, the investment manager of the separately managed account is required to deposit, either in cash or securities, an amount equal to a certain percentage of the notional value of the contract. Subsequent payments are then made or received by the Plan, depending on the daily fluctuation in the value of the underlying contracts.

As of December 31, 2025 and 2024, the Plan held futures contracts with a notional amount of approximately $998,000 and $629,000, respectively. Notional amounts do not quantify risk or represent assets or liabilities of the Plan, but are used in the calculation of the cash settlements under the contracts. The fair value of these derivative contracts was not material at December 31, 2025 and 2024. Changes in fair value are accounted for as investment income (loss) within net appreciation in fair value of investments and totaled approximately $32,000 for the year ended December 31, 2025.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

Short sales

One of the investment options structured as a separately managed account utilizes short sales as part of its investment strategy. Short sales are transactions in which the separately managed account sells an investment it does not own in anticipation of a decline in value of that investment. To complete the transaction, the separately managed account must borrow the investment to make delivery to the buyer. The separately managed account is obligated to replace the investment borrowed by purchasing the investment at market price at the time of replacement. The price at such time may be more or less than the price at which the investment was sold by the separately managed account. When an investment is sold short, a decrease in the value of the investment will be recognized as a gain and an increase in the value of the investment will be recognized as a loss.

The following tables summarize the basis used to measure investment assets and liabilities at fair value at December 31, 2025 and 2024 (dollars in thousands):


	Basis of Fair Value Measurement
	Quoted		Significant
	Prices in		Other		Significant
	Active		Observable		Unobservable		Measured at
2025	Markets		Inputs		Inputs		NAV		Total
Assets - Investments:
Common stock	$	5,585,157	$	—	$	—	$	—	$	5,585,157
Mutual funds		120,058		—		—		—		120,058
REITs		23,846		—		—		—		23,846
Collective trust funds		—		—		—		11,120,673		11,120,673
Corporate debt		—		227,462		—		—		227,462
Government debt		—		184,339		—		—		184,339
Private 40-Act mutual funds		—		—		—		398,213		398,213
Total investments, at fair value	$	5,729,061	$	411,801	$	—	$	11,518,886	$	17,659,748


	Basis of Fair Value Measurement
	Quoted		Significant
	Prices in		Other		Significant
	Active		Observable		Unobservable		Measured at
2025	Markets		Inputs		Inputs		NAV		Total
Liabilities - Investments sold short:
Government debt	$	—	$	327,342	$	—	$	—	$	327,342
Total investments sold short, at fair value	$	—	$	327,342	$	—	$	—	$	327,342

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued


		Basis of Fair Value Measurement
		Quoted			Significant
		Prices in			Other			Significant
		Active			Observable			Unobservable			Measured at
2024		Markets			Inputs			Inputs			NAV			Total
Assets - Investments:
Common stock		$	5,066,260		$	—		$	—		$	—		$	5,066,260
Mutual funds			108,326			—			—			—			108,326
REITs			25,888			—			—			—			25,888
Collective trust funds			—			—			—			9,592,890			9,592,890
Corporate debt			—			235,392			—			—			235,392
Government debt			—			154,812			—			—			154,812
Private 40-Act mutual funds			—			—			—			393,035			393,035
Total investments, at fair value		$	5,200,474		$	390,204		$	—		$	9,985,925		$	15,576,603


		Basis of Fair Value Measurement
		Quoted			Significant
		Prices in			Other			Significant
		Active			Observable			Unobservable			Measured at
2024		Markets			Inputs			Inputs			NAV			Total
Liabilities - Investments sold short:
Government debt		$	—		$	19,750		$	—		$	—		$	19,750
Total investments sold short, at fair value		$	—		$	19,750		$	—		$	—		$	19,750

Participants are permitted to make redemptions from the Plan’s investment options on a daily basis, however, certain investments valued at NAV as a practical expedient have redemption requirements and in some cases restrictions for a Plan level redemption. The following tables provide the redemption requirements and restrictions, if any, for those investments as of December 31, 2025 and 2024 (dollars in thousands). In addition, the tables provide the investment strategies for certain investments measured at NAV as a practical expedient, if that investment is a fund that does not file an annual report on Form 5500 as a direct-filing entity.


		2025
		Fair value			Redemption		Redemption
		(NAV)			frequency		notice period		Restrictions
Funds filing as direct filing entity:
Collective trusts		$	11,120,673		Daily		0 - 5 days		—

Funds not filing as direct filing entity:
Private 40-Act mutual funds
Short-term fixed income			398,213		Daily		—		Yes (a)
		$	11,518,886

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued


		2024
		Fair value			Redemption		Redemption
		(NAV)			frequency		notice period		Restrictions
Funds filing as direct filing entity:
Collective trusts		$	9,592,890		Daily		0 - 5 days		—

Funds not filing as direct filing entity:
Private 40-Act mutual funds
Short-term fixed income			393,035		Daily		—		Yes (a)
		$	9,985,925

(a)

The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or 1% of the respective fund’s net assets during any 90-day period for any one shareholder. In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the respective fund in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind. Redemption proceeds are ordinarily wired within three business after receipt of the redemption request, but may take up to seven days.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Contributions

Contributions from Plan participants and the matching contributions from the employer are recorded in the year in which the employee contributions are withheld from compensation. Freedom 2 Save employer contributions, true-up employer matching contributions, and the 3% annual employer contribution are accrued in the year in which they are earned.

Administrative Expenses

Participants are charged transaction fees for loan processing, which are included in other expenses and commissions on purchases and sales of Abbott shares and sales of AbbVie stock, which are included in net appreciation in fair value of investments. Investment fees for mutual funds, REITs, collective trusts, and managed accounts are charged against the net assets of the respective fund and are also included in net appreciation in fair value of investments. Abbott pays other recordkeeping and administration fees, where applicable. Expenses that are paid by Abbott are excluded from these financial statements.

Payment of Benefits

Benefits are recorded when paid.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2025 and 2024 is presented below:


		2025			2024
Abbott common shares, 22,899,112 and 24,199,951 shares, respectively (dollars in thousands)		$	2,869,030		$	2,737,256
Market price per share		$	125.29		$	113.11

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Trustee and shares of the Trustee’s common stock. A significant portion of the Plan’s assets is invested in Abbott common shares.

These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2025, the Plan received $55.5 million in common stock dividends from Abbott.

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the Trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

NOTE F - TAX STATUS

The Internal Revenue Service (“IRS”) has determined and informed Abbott by a letter dated April 13, 2022, that the Plan and related Trust are designed in accordance with applicable sections of the IRC. The Plan has been amended since the applicable date of the determination letter. However, the Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable requirements of the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS or other applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2025 and 2024, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. There are currently no audits in progress.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE G - RISKS AND UNCERTAINTIES

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

NOTE H - SUBSEQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2025 through the date these financial statements were issued. Other than described below, management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

The following changes took effect on January 1, 2026:

Fidelity Investments replaced Alight Solutions as the recordkeeper of the Plan. For the Abbott and AbbVie common stock investment options only, Fidelity Management Trust Company replaced The Northern Trust Company as custodian and trustee.

An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will receive employer matching contributions each payroll period instead of a true-up employer matching contribution shortly after the end of the year. The sum of an enrolled Freedom 2 Save participant’s employer matching contributions and Freedom 2 Save employer contribution will not exceed 5% of the participant’s eligible earnings for the plan year. Additionally, Freedom 2 Save participants will not be required to be actively employed or on a qualifying leave of absence on the last day of the plan year in order to receive the Freedom 2 Save employer contribution.

A participant who has a balance in the AbbVie common stock investment option will have dividends invested across the participant’s investment elections on file for future contributions.

Non-vested portions of employer contributions and earnings thereon are forfeited as of the date the participating employee receives a distribution or, if later, the end of the plan year in which the participating employee has been separated from Abbott for a period of five years.

SUPPLEMENTAL SCHEDULE

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - employer securities
*		ABBOTT LABORATORIES, common shares						$	2,869,030

		Common stock
		5TH 3RD BANCORP COM							964
		ABBVIE INC.							2,445,873
		ACADIA HEALTHCARE CO INC COM							40
		ACUITY INC							343
		ADT INC DEL COM							128
		ADVANCED DRAIN SYS INC DEL COM							317
		AECOM							391
		AES CORP COM							315
		AFFILIATED MANAGERS GROUP INC COM STK							240
		AFFIRM HLDGS INC CL A							257
		AGCO CORP COM							203
		AGILENT TECHNOLOGIES INC COM							1,199
		AIR LEASE CORP CL A							208
		AKAMAI TECHNOLOGIES INC COM STK							380
		ALASKA AIR GROUP INC COM							146
		ALBEMARLE CORP COM							518
		ALBERTSONS COS INC CL A							208
		ALIGN TECHNOLOGY INC COM							331
		ALLEGION PLC COMMON STOCK							426
		ALLEGRO MICROSYSTEMS INC DEL COM							103
		ALLIANT ENERGY CORP COM							509
		ALLISON TRANSMISSION HOLDING							208
		ALLSTATE CORP COM							1,700
		ALLY FINL INC COM							342
		AMCOR							595
		AMDOCS ORD GBP0.01							272
		AMENTUM HLDGS INC COM							145
		AMER FINL GROUP INC OH COM STK							280
		AMER SPORTS INC COM							174
		AMEREN CORP COM							824
		AMERICAN AIRLINES INC COM							295
		AMERICAN WTR WKS CO INC NEW COM							787
		AMERIPRISE FINL INC COM							130
		AMETEK INC NEW COM							1,464
		AMKOR TECHNOLOGY INC COM							136
		ANGLOGOLD ASHANTI PLC ORD							1,162
		ANTERO MIDSTREAM CORPORATION							185
		ANTERO RES CORP COM							307
		APA CORP COM							271
		API GROUP CORPORATION COM							431
		APPLIED INDL TECHNOLOGIES INC COM							297
		APTARGROUP INC COM							247
		APTIV PLC NEW ORD							511
		ARAMARK COM							296
		ARCH CAPITAL GROUP COM STK							1,056
		ARCHER-DANIELS-MIDLAND CO COM							849
		ARMSTRONG WORLD INDS INC NEW COM STK							180
		ARROW ELECTR INC COM							175
		ASHLAND INC COM							82
		ASSURANT INC COM							377
		ASSURED GUARANTY LTD COMMON STK							121
		AST SPACEMOBILE INC CL A CL A							37

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		ATI INC COM							478
		ATMOS ENERGY CORP COM							833
		AURORA INNOVATION INC CL A COM							138
		AUTONATION INC COM							168
		AVANTOR INC COM							234
		AVERY DENNISON CORP COM							432
		AVIS BUDGET GROUP INC COM STK							47
		AVNET INC COM							117
		AXALTA COATING SYSTEMS LTD COM							213
		AXIS CAPITAL HOLDINGS LTD COM							245
		BAKER HUGHES CO							1,396
		BALL CORP COM							446
		BANK NEW YORK MELLON CORP COM STK							2,329
		BANK OZK COM							152
		BATH & BODY WORKS INC COM							128
		BAXTER INTL INC COM							306
		BELLRING BRANDS INC COM							104
		BERKLEY W R CORP COM							631
		BEST BUY INC COM STK							401
		BILL HOLDINGS INC COM							157
		BIO RAD LABORATORIES INC CL A CL A							174
		BIOGEN INC COMMON STOCK							792
		BIOMARIN PHARMACEUTICAL INC COM							348
		BIO-TECHNE CORP COM							279
		BIRKENSTOCK HOLDING PLC COM NPV							49
		BJS WHSL CLUB HLDGS INC COM							310
		BLOCK H & R INC COM							142
		BLOCK INC							687
		BOK FINL CORP COM NEW							79
		BORG WARNER INC COM							295
		BOSTON BEER INC CL A CL A							51
		BOYD GAMING CORP COM							148
		BRIGHT HORIZONS FA COM							154
		BRIGHTHOUSE FINL INC COM							114
		BROADRIDGE FINL SOLUTIONS INC COM STK							76
		BROOKFIELD RENEWABLE CORP NEW CL A							161
		BROWN & BROWN INC COM							638
		BROWN FORMAN CORP CL A CL A							36
		BROWN-FORMAN INC CL B NON-VTG COM							119
		BRUKER CORP							151
		BRUNSWICK CORP COM							150
		BUILDERS FIRSTSOURCE INC COM STK							345
		BUNGE GLOBAL SA F COMMON STOCK							371
		BWX TECHNOLOGIES INC COM							401
		C H ROBINSON WORLDWIDE INC COM NEW							584
		CACI INTL INC CL A CL A							358
		CAESARS ENTMT INC NEW COM							146
		CARDINAL HLTH INC							754
		CARIS LIFE SCIENCES INC COM							10
		CARLISLE COMPANIES INC COM							361
		CARLYLE GROUP INC COM							479
		CARMAX INC COM							175
		CARNIVAL CORP COM PAIRED							707
		CARPENTER TECHNOLOGY CORP COM							386
		CASEYS GEN STORES INC COM							536
		CBOE GLOBAL MARKETS INC							821

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		CBRE GROUP INC CL A CL A							1,316
		CCC INTELLIGENT SOLUTIONS HLDGS INC COM							140
		CDW CORP COM							511
		CELANESE CORP DEL COM STK							143
		CENTENE CORP DEL COM							619
		CENTERPOINT ENERGY INC COM							774
		CERTARA INC COM							35
		CF INDS HLDGS INC COM							386
		CHARLES RIV LABORATORIES INTL INC COM							303
		CHARTER COMMUNICATIONS INC NEW CL A CL A							539
		CHEMED CORP NEW COM							168
		CHENIERE ENERGY INC COM NEW							706
		CHOICE HOTELS INTL INC COM							57
		CHORD ENERGY CORPORATION COM							162
		CHURCH & DWIGHT INC COM							635
		CHURCHILL DOWNS INC COM							36
		CIENA CORP COM NEW							1,021
		CIN FNCL CORP COM							768
		CIRCLE INTERNET GROUP INC. COM							99
		CIRRUS LOGIC INC COM							188
		CITIZENS FINL GROUP INC COM							782
		CLARIVATE PLC							38
		CLEAN HBRS INC COM							367
		CLEARWAY ENERGY INC CL A CL A							35
		CLEARWAY ENERGY INC CL C CL C							83
		CLEVELAND CLIFFS							229
		CLOROX CO COMMON STOCK							381
		CMS ENERGY CORP COM							662
		CNA FNCL CORP COM							30
		CNH INDUSTRIAL NV COM STK							254
		COCA-COLA CONSOLIDATED INC COM							212
		COGNEX CORP COM							192
		COGNIZANT TECH SOLUTIONS CORP CL A							1,240
		COHERENT CORP COM							887
		COINBASE GLOBAL INC COM CL A							1,407
		COLUMBIA BKG SYS INC COM							255
		COLUMBIA SPORTSWEAR CO COM							44
		COM ALCOA CORPORATION COM							426
		COMM BANCSHARES INC COM							208
		CONAGRA BRANDS INC COM							254
		CONCENTRIX CORP							57
		CONS EDISON INC COM							1,109
		CONSTELLATION BRANDS INC CL A CL A							607
		CORE & MAIN INC COM CL A COM CL A							128
		COREBRIDGE FINL INC COM							245
		CORNING INC COM							2,107
		CORTEVA INC COM							1,419
		COSTAR GROUP INC COM							757
		COTERRA ENERGY INC COM							614

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost^**		value
		Common stock - continued
		COTY INC COM CL A COM CL A							34
		CRANE CO NEW COM							280
		CRANE NXT CO COM							71
		CREDIT ACCEP CORP MICH COM							55
		CROCS INC COM							133
		CROWN HLDGS INC COM							369
		CULLEN / FROST BANKERS INC COM							239
		CUMMINS INC							2,174
		CURTISS WRIGHT CORP COM							636
		D R HORTON INC COM							1,184
		DARDEN RESTAURANTS INC COM							31
		DARLING INGREDIENTS INC COMSTK							154
		DAYFORCE INC							299
		DELTA AIR LINES INC DEL COM NEW COM NEW							1,394
		DENTSPLY SIRONA INC COM							71
		DEVON ENERGY CORP NEW COM							710
		DIAMONDBACK ENERGY INC COM							873
		DICKS SPORTING GOODS INC OC-COM OC-COM							384
		DILLARDS INC CL A COM							54
		DOCUSIGN INC COM							106
		DOLBY LABORATORIES INC CL A COM STK							118
		DOLLAR GEN CORP NEW COM							902
		DOLLAR TREE INC COM STK							732
		DOMINOS PIZZA INC COM							282
		DONALDSON INC COM							313
		DOUBLEVERIFY HLDGS INC COM							25
		DOVER CORP COM							818
		DOW INC							514
		DROPBOX INC CL A CL A							116
		DT MIDSTREAM INC COM							372
		DTE ENERGY CO COM							831
		DUPONT DE NEMOURS INC COMMON STOCK							522
		DXC TECHNOLOGY CO COM							86
		E L F BEAUTY INC COM							130
		EAGLE MATLS INC COM							190
		EAST WEST BANCORP INC COM							474
		EASTMAN CHEM CO COM							226
		EBAY INC COM							1,238
		EDISON INTL COM							708
		ELANCO ANIMAL HEALTH INC COM							344
		ELECTR ARTS COM							1,584
		ELEMENT SOLUTION INC COM							175
		EMCOR GROUP INC COM							549
		ENCOMPASS HEALTH CORP COM							329
		ENTEGRIS INC COM							324
		ENTERGY CORP NEW COM							1,273
		ENVISTA HLDGS CORP COM							113
		EPAM SYS INC COM STK							341
		EQT CORP COM							1,031
		EQUIFAX INC COM							678
		ESAB CORPORATION COM							196
		ESSENTIAL UTILS INC COM							334
		ESTEE LAUDER COMPANIES INC CL A							794
		ETSY INC COM							72
		EURONET WORLDWIDE INC COM							90
		EVERCORE INC							389

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		EVERCORE INC							389
		EVEREST GROUP LTD							374
		EVERGY INC COM NPV							515
		EVERSOURCE ENERGY COM							775
		EVERUS CONSTR GROUP INC COM							138
		EXACT SCIENCES CORP COM							556
		EXELIXIS INC COM STK							68
		EXELON CORP COM							1,365
		EXPAND ENERGY CORP							776
		EXPEDITORS INTL WASH INC COM							621
		F N B CORP PA COM							186
		F&G ANNUITIES & LIFE INC COM							15
		F5 INC COM STK NPV							455
		FACTSET RESH SYS INC COM STK							315
		FAIR ISAAC CORPORATION COM							216
		FASTENAL CO COM							253
		FERGUSON ENTERPRISES INC							1,240
		FERMI INC COM USD0.001							10
		FIDELITY NATL FINL INC							435
		FIDELITY NATL INFORMATION SVCS INC COM STK							1,082
		FIFTH THIRD BANK							343
		FIGURE TECHNOLOGY SOLUTIONS INC CL A CL A							36
		FIRST AMERN FINL CORP COM STK							190
		FIRST CTZNS BANCSHARES INC CL A CL A							601
		FIRST HAWAIIAN INC COM							100
		FIRST HORIZON CORPORATION COM							368
		FIRST SOLAR INC COM							821
		FIRSTENERGY CORP COM							764
		FIVE BELOW INC COM USD0.01							313
		FLEX LTD COM USD0.01							695
		FLOOR & DECOR HLDGS INC CL A CL A							138
		FLOWERS FOODS INC COM							66
		FLOWSERVE CORP COM							284
		FLUTTER ENTERTAINMENT PLC							182
		FMC CORP COM (NEW)							54
		FORD MTR CO							1,579
		FORTIVE CORP COM MON STOCK							539
		FORTUNE BRANDS INNOVATIONS INC							186
		FOX CORP CL A CL A							477
		FOX CORP CL B CL B							305
		FREEDOM HLDG CORP COM NEW COM							12
		FRESHPET INC COM							64
		FRKLN RES INC COM							227
		FRONTIER AIRLINES							286
		FTI CONSULTING INC COM							166
		GAMESTOP CORP NEW CL A							257
		GAP INC COM							179
		GARMIN LTD COMMON STOCK							1,019
		GATES INDL CORP PL COM							169
		GCI LIBERTY INC COM SER C							31
		GCI LIBERTY INC SER A GCI GROUP COM							4
		GE HEALTHCARE TECHNOLOGIES INC COM							1,152
		GEN DIGITAL INC COM							412
		GENERAC HLDGS INC COM STK							248
		GENERAL MILLS INC COM							784
		GENPACT LIMITED COM STK							233
		GENTEX CORP COM							163
		GENUINE PARTS CO COM							526
		GLOBAL PMTS INC COM							576
		GLOBALFOUNDRIES INC							110
		GLOBANT SA							79
		GLOBE LIFE INC COM							361
		GLOBUS MED INC CL A NEW COM STK							306
		GRACO INC COM							421

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		GRAINGER W W INC COM							200
		GRAND CANYON ED INC COM STK							100
		GRAPHIC PACKAGING HLDG CO COM STK							136
		GXO LOGISTICS INC COM							182
		HALLIBURTON CO COM							739
		HAMILTON LANE INC CL A CL A							59
		HANOVER INS GROUP INC COM							198
		HARLEY DAVIDSON COM							69
		HASBRO INC COM							337
		HAYWARD HLDGS INC COM							95
		HENRY SCHEIN INC COMMON STOCK							246
		HERSHEY COMPANY COM STK USD1							721
		HEWLETT PACKARD ENTERPRISE CO COM							973
		HEXCEL CORP NEW COM							180
		HF SINCLAIR CORPORATION COM							199
		HOLOGIC INC COM							516
		HORMEL FOODS CORP COM							212
		HOULIHAN LOKEY INC CL A CL A							184
		HOWARD HUGHES HLDGS INC COM							76
		HP INC COM							648
		HUBBELL INC COM							730
		HUMANA INC COM							953
		HUNT J B TRANS SVCS INC COM							465
		HUNTINGTON BANCSHARES INC COM							831
		HUNTINGTON INGALLS INDS INC COM							413
		HUNTSMAN CORP COM STK							50
		HYATT HOTELS CORP COM CL A COM CL A							202
		IAC INC COM NEW							79
		IDACORP INC COM							212
		IDEX CORP COM							416
		ILLUMINA INC COM							634
		INCYTE CORP COM							358
		INGERSOLL RAND INC COM							973
		INGRAM MICRO HLDG CORP COM							11
		INGREDION INC COM							217
		INSMED INC COM							71
		INTL FLAVORS & FRAGRANCES INC COM							528
		INTL PAPER CO COM							639
		INVESCO LTD COM STK							296
		IONIS PHARMACEUTICALS INC COM							32
		IPG PHOTONICS CORP COM							54
		IQVIA HLDGS INC COM							1,173
		IRIDIUM COMMUNICATIONS INC COM STK							45
		ITT INC COM							452
		JABIL INC COM							258
		JACK HENRY & ASSOC INC COM							406
		JACOBS SOLUTIONS INC COM							488
		JAMES HARDIE INDUSTRIES PLC COM							34
		JANUS HENDERSON GROUP PLC							181

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		JAZZ PHARMACEUTICALS PLC COM							305
		JEFFERIES FINL GROUP INC COM							222
		JONES LANG LASALLE INC COM STK							357
		KBR INC COM							144
		KEMPER CORP DEL COM							79
		KENVUE INC COM							1,010
		KEYCORP NEW COM							603
		KEYSIGHT TECHNOLOGIES INC COM							1,074
		KINDER MORGAN INC DEL COM							1,652
		KIRBY CORP COM							191
		KNIGHT-SWIFT TRANSN HLDGS INC CL A							253
		KRAFT HEINZ CO COM							640
		KROGER CO COM							1,177
		KYNDRYL HLDGS INC COM							177
		L3HARRIS TECHNOLOGIES INC COM							1,688
		LABCORP HLDGS INC COM							649
		LAMB WESTON HLDGS INC COM							175
		LANDSTAR SYS INC COM							156
		LATTICE SEMICONDUCTOR CORP COM							46
		LEAR CORP COM NEW COM NEW							183
		LEIDOS HLDGS INC COM							712
		LENNAR CORP CL A CL A							654
		LENNAR CORP CL B CL B							24
		LEONARDO DRS INC COM							50
		LIBERTY BROADBAND CORP COM SER A COM SERA							12
		LIBERTY BROADBAND CORP COM SER C COM SERC							141
		LIBERTY GLOBAL LTD. COM USD0.01 CLASS C							50
		LIBERTY GLOBAL LTD. COMMON STOCK							51
		LIBERTY LIVE HLDGS INC COM SER A							49
		LIBERTY LIVE HLDGS INC SER C							119
		LIBERTY MEDIA CORP SER A							39
		LIBERTY MEDIA CORP SER C							446
		LINCOLN ELEC HLDGS INC COM							403
		LINCOLN NATL CORP COM							233
		LITHIA MTRS INC COM CL A							232
		LITTELFUSE INC COM							192
		LKQ CORP COM LKQ CORP							240
		LOAR HOLDINGS INC COM							9
		LOEWS CORP COM							552
		LOUISIANA-PACIFIC CORP COM							158
		LUCID GROUP INC COM NEW							42
		LULULEMON ATHLETICA INC COM							283
		LUMENTUM HLDGS INC COM							742
		LYFT INC CL A CL A							193
		LYONDELLBASELL IND N V							343
		M & T BK CORP COM							957
		MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC COM STK							253
		MACYS INC COM STK							181
		MADISON SQUARE GARDEN SPORTS CORP							127
		MANPOWERGROUP INC							42
		MAPLEBEAR INC COM							239
		MARATHON PETE CORP COM							1,531
		MARKEL GROUP INC							660
		MARKETAXESS HLDGS INC COM STK							208
		MARTIN MARIETTA MATLS INC COM							1,155

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		MASCO CORP COM							415
		MASTEC INC COM							330
		MATADOR RES CO COM							149
		MATCH GROUP INC NEW COM							238
		MATTEL INC COM STOCK							190
		MC CORMICK & CO INC COM NON-VTG							524
		MDU RES GROUP INC COM							127
		METTLER-TOLEDO INTL INC COM							888
		MGIC INVT CORP WIS COM							198
		MGM RESORTS INTERNATIONAL COM							231
		MICROCHIP TECHNOLOGY INC COM							1,041
		MIDDLEBY CORP COM							233
		MILLICOM INTERNATIONAL CELLULAR COM							179
		MKS INC							336
		MODERNA INC COM							326
		MOHAWK INDS INC COM							172
		MOLINA HEALTHCARE INC COM							124
		MOLSON COORS BEVERAGE COMPANY COM							242
		MONGODB INC CL A CL A							932
		MORNINGSTAR INC COM STK							52
		MOSAIC CO/THE							238
		MP MATERIALS CORP COM							205
		MSA SAFETY INC COM							178
		MSC INDL DIRECT INC CL A COM							115
		MSCI INC COM							660
		MUELLER INDS INC COM							385
		NASDAQ INC							1,366
		NATL FUEL GAS CO COM							222
		NCINO INC NEW COM							74
		NETAPP INC COM STK							398
		NEUROCRINE BIOSCIENCES INC COM							61
		NEW YORK TIMES CO CL A							344
		NEWELL BRANDS INC COM							48
		NEWMARKET CORP COM							120
		NEWS CORP COM CL A							304
		NEWS CORP COM CL B							115
		NEXSTAR MEDIA GROUP INC COMMON STOCK							165
		NIQ GLOBAL INTELLIGENCE PLC							12
		NISOURCE INC COM							602
		NORDSON CORP COM							394
*		NORTHERN TR CORP COM							797
		NORWEGIAN CRUISE LINE HLDGS LTD COM							30
		NOV INC COM							170
		NUCOR CORP COM							1,154
		NUTANIX INC CL A CL A							313
		NVENT ELECTRIC PLC COM							503
		NVR INC COM STK							613
		OCCIDENTAL PETROLEUM CORP							895
		OGE ENERGY CORP COM							267
		OKTA INC CL A CL A							271
		OLD DOMINION FREIGHT LINE INC COM							841
		OLD REPUBLIC INTERNATIONAL CORP COM							321
		OLIN CORP COM							74
		OLLIES BARGAIN OUTLET HLDGS INC COM							207
		OMNICOM GROUP INC COM							799
		ON SEMICONDUCTOR CORP COM							684
		ONEMAIN HLDGS INC COM							254
		ONEOK INC COM STK							1,422
		ONTO INNOVATION INC							184
		ORD SHS							32
		ORGANON & CO COM							58

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		OSHKOSH CORPORATION							251
		OTIS WORLDWIDE CORP COM							1,056
		OVINTIV INC COM							308
		OWENS CORNING NEW COM STK							286
		PACKAGING CORP AMER COM							564
		PARSONS CORP DEL COM							102
		PAYCHEX INC COM							762
		PAYCOM SOFTWARE INC COM							115
		PAYLOCITY HLDG CORP COM							16
		PEGASYSTEMS INC COM							108
		PENN ENTERTAINMENT INC							66
		PENSKE AUTOMOTIVE GROUP INC COM STK							87
		PENTAIR PLC COM							519
		PERFORMANCE FOOD GROUP CO COM							370
		PERMIAN RES CORP CL A							308
		PERRIGO COMPANY LIMITED COM							57
		PG& E CORP COM							1,090
		PHILLIPS 66 COM							1,494
		PILGRIMS PRIDE CORP							50
		PINNACLE							209
		PINNACLE W. CAP CORP COM							329
		PINTEREST INC CL A CL A							238
		POOL CORP COM STK							189
		POPULAR INC COM NEW COM							234
		POST HLDGS INC COM STK							149
		PPG IND INC COM							713
		PPL CORP COM							800
		PRIMERICA INC COM							257
		PRIMO BRANDS CORPORATION COM							130
		PRINCIPAL FINL GROUP INC COM STK							592
		PROSPERITY BANCSHARES INC COM							194
		PRUDENTIAL FINL INC COM							1,221
		PTC INC COM							568
		PUB SERVICE ENTERPRISE GROUP INC COM							1,242
		PULTE GROUP INC							698
		PURE STORAGE INC CL A CL A							94
		PVH CORP COM							99
		QIAGEN							300
		QNITY ELECTRONICS INC COM							529
		QORVO INC COM							220
		QUANTA SVCS INC COM							433
		QUANTUMSCAPE CORP							145
		QUEST DIAGNOSTICS INC COM							600
		QXO INC COM PAR VALUE							367
		RALLIANT CORP COM							177
		RALPH LAUREN CORP CL A CL A							378
		RANGE RES CORP COM							256
		RAYMOND JAMES FNCL INC COM STK							889
		RB GLOBAL INC COM NPV							542
		RBC BEARINGS INC COM							343
		REGAL REXNORD CORPORATION COM STK							286
		REGIONS FINL CORP NEW COM							751
		REINSURANCE GROUP AMER INC COM NEW STK							414
		RELIANCE INC COM NPV							462
		RENAISSANCE RE HLDGS LTD COM							393
		REPLIGEN CORP COM STK							234
		RESMED INC COM							822
		RESTAURANT BRANDS INTL INC COM NPV							248
		REVOLUTION MEDICINES INC COM							426

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		REVVITY INC							354
		REYNOLDS CONSUMER PRODS INC COM							38
		RH COM							71
		RIVIAN AUTOMOTIVE INC							479
		RLI CORP COM							152
		ROBERT HALF INC COM							82
		ROBINHOOD MKTS INC COM CL A COM CL A							2,244
		ROCKET COS INC CL A CL A							564
		ROCKWELL AUTOMATION							1,247
		ROIVANT SCIENCES LTD COM							259
		ROKU INC COM CL A COM CL A							375
		ROSS STORES INC COM							1,427
		ROYAL GOLD INC COM STK							563
		ROYALTY PHARMA PLC COM							465
		RPM INTL INC							404
		RUBRIK INC COM							127
		RYDER SYS INC COM							231
		S.W. AIRL CO COM							530
		SAIA INC COM STK							268
		SAILPOINT INC COM							37
		SANDISK CORP COM							993
		SAREPTA THERAPEUTICS INC COM							10
		SCHNEIDER NATL INC WIS CL B CL B							42
		SCIENCE APPLICATIONS INTL CORP NEW COM							142
		SCOTTS MIRACLE-GRO CLASS’A’COM NPV							79
		SEABOARD CORP DEL COM							36
		SEALED AIR CORP NEW COM STK							187
		SEI INVTS CO COM							264
		SENSATA TECHNOLOGIES B V HOLDING							148
		SENTINELONE INC CL A COM CL A COM							38
		SERVICE CORP INTL COM							339
		SHARKNINJA COM							239
		SILGAN HLDGS INC COM							112
		SIMPSON MFG INC COM							194
		SIRIUS XM HLDGS INC NEW COM							117
		SITEONE LANDSCAPE SUPPLY INC COM							115
		SKYWORKS SOLUTIONS INC COM							291
		SLM CORP COM							153
		SM ENERGY CO							78
		SMITH A O CORP COM							235
		SMITHFIELD FOODS INC COM							31
		SMUCKER J M CO COM NEW							315
		SMURFIT WESTROCK LTD							623
		SNAP-ON INC COM							546
		SOFI TECHNOLOGIES INC COM							849
		SOLVENTUM CORP COM COM							363
		SONOCO PROD CO COM							134
		SOTERA HEALTH CO COM							101
		SOUTHSTATE BK CORP COM							292
		SS&C TECHNOLOGIES HLDGS INC COM							566
		STANDARDAERO INC. COM							116
		STANLEY BLACK & DECKER INC COM							356
		STATE STR CORP COM							1,116
		STEEL DYNAMICS INC COM							664
		STERIS PLC ORD							771
		STIFEL FINL CORP COM							392

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		SUPER MICRO COMPUTER INC COM NEW							252
		SYNCHRONY FINL COM							929
		SYNOVUS							213
		SYSCO CORP COM							506
		T ROWE PRICE GROUP INC							689
		TAKE-TWO INTERACTIVE SOFTWARE INC COM STK							942
		TALEN ENERGY CORP NEW COM							527
		TAPESTRY INC COM							67
		TD SYNNEX CORPORATION COM							353
		TECHNIPFMC PLC COM USD1							550
		TELEDYNE TECHNOLOGIES INC COM							731
		TELEFLEX INC COM							167
		TENET HEALTHCARE CORP COM NEW.							536
		TERADATA CORP DEL COM STK							68
		TERADYNE INC COM							938
		TETRA TECH INC NEW COM							221
		TEXTRON INC COM							476
		TFS FINL CORP COM STK							24
		THE CAMPBELLS COMPANY							168
		THE COOPER COMPANIES, INC.							498
		THE HARTFORD INSURANCE GROUP INC COM							1,197
		THOR INDS INC COM STK							160
		TIMKEN CO COM							162
		TKO GROUP HLDGS INC COM							255
		TOLL BROS INC COM							402
		TOPBUILD CORP COM							337
		TORO CO COM							239
		TPG PARTNERS LLC CL A COM							19
		TRADEWEB MKTS INC CL A CL A							359
		TRANSUNION COM							517
		TRAVEL + LEISURE CO COM							90
		TREX CO INC COM							117
		TRIMBLE INC COM TRIMBLE INC							577
		TRUMP MEDIA & TECHNOLOGY GROUP CORP							31
		TWILIO INC CL A CL A							519
		TYLER TECHNOLOGIES INC COM STK							103
		TYSON FOODS INC CL A COM (DELAWARE)							506
		UGI CORP NEW COM							249
		U-HAUL HOLDING COMPANY							88
		U-HAUL HOLDING COMPANY							9
		UIPATH INC CL A CL A							204
		ULTA BEAUTY INC							634
		UNDER ARMOR INC CL A							29
		UNDER ARMOUR INC CL C COM							29
		UNITED AIRLINES HOLDINGS INC COM							1,121
		UNITED RENTALS INC COM							1,590
		UNITED THERAPEUTICS CORP DEL COM STK							639
		UNITY SOFTWARE INC COM							414
		UNIVERSAL DISPLAY CORP COM							159
		UNUM GROUP							405
		UNVL HEALTH SERVICES INC CL B COM							362
		US FOODS HLDG CORP COM							536
		UWM HLDGS CORP COM							21
		V F CORP COM							196
		VAIL RESORTS INC COM							26
		VALERO ENERGY CORP COM STK NEW							1,531
		VALMONT INDS INC COM							241
		VALVOLINE INC COM							13
		VEEVA SYS INC CL A COM CL A COM							205
		VERALTO CORP COM							446
		VERISIGN INC COM							627
		VERISK ANALYTICS INC COM							389

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Common stock - continued
		VIATRIS INC							444
		VIKING THERAPEUTICS INC COM							112
		VIPER ENERGY INC NEW CL A							203
		VIRTU FINL INC CL A CL A							84
		VONTIER CORP COM							167
		VOYA FINL INC COM							226
		VULCAN MATERIALS CO COM							1,167
		WABTEC CORP COM							1,120
		WARNER BROS DISCOVERY INC							2,077
		WATERS CORP COM							334
		WATSCO INC COM							362
		WAYFAIR INC CL A CL A							239
		WEATHERFORD INTL LTD COMMON STOCK							174
		WEBSTER FNCL CORP WATERBURY CONN COM							318
		WEC ENERGY GROUP INC COM							1,069
		WENDYS CO COM							23
		WESCO INTL INC COM							362
		WEST PHARMACEUTICAL SVCS INC COM							613
		WESTERN ALLIANCE BANCORPORATION COM							221
		WESTERN UNION CO							98
		WESTLAKE CORPORATION COM							80
		WESTN DIGITAL CORP COM							1,836
		WEX INC COM							146
		WHIRLPOOL CORP COM							121
		WHITE MOUNTAINS INSURANCE GROUP							158
		WILLIAMS SONOMA INC COM							557
		WILLIS TOWERS WATSON PLC							991
		WILLSCOT HOLDINGS CORPORATION COM							77
		WINTRUST FINL CORP COM							284
		WOODWARD INC COM							561
		WYNDHAM HOTELS & RESORTS INC COM							20
		WYNN RESORTS LTD COM							285
		XCEL ENERGY INC COM							1,355
		XP INC COM CLASS A							183
		XPO INC COM							382
		XYLEM INC COM							1,019
		YETI HLDGS INC COM							110
		YUM BRANDS INC COM							868
		ZEBRA TECHNOLOGIES CORP CL A							382
		ZILLOW GROUP INC COM							105
		ZILLOW GROUP INC COM CLASS C							344
		ZIMMER BIOMET HLDGS INC COM							552
		ZIONS BANCORPORATION N A							259
		ZOOM COMMUNICATIONS INC							711
		ZOOMINFO TECHNOLOGIES INC COM							83
		Total Common stock							5,585,157

		Mutual fund
		PIMCO ALL ASSET FUND							120,058

		REITs
		1ST INDL RLTY TR INC COM							226
		AGNC INVT CORP COM							333
		AGREE RLTY CORP COM							242
		ALEXANDRIA REAL ESTATE EQUITIES INC COM							259
		AMERICAN HOMES 4 RENT COMMON STOCK							339
		AMERICOLD RLTY TR INC COM							113

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		REITs - continued
		ANNALY CAPITAL MANAGEMENT INC COM							487
		AVALONBAY CMNTYS REIT							798
		BRIXMOR PPTY GROUP INC COM							249
		BXP INC							332
		CAMDEN PPTY TR SH BEN INT							367
		COUSINS PPTYS INC							133
		CROWN CASTLE INC COM							1,194
		CUBESMART							254
		DIGITAL RLTY TR INC COM							1,648
		EASTGROUP PPTYS INC REIT							290
		EPR PPTYS COM SH BEN INT COM SH BEN INT							117
		EQTY LIFESTYLE PPTYS INC REIT							361
		EQTY RESDNTL EFF 5/15/02							738
		ESSEX PPTY TR REIT							511
		EXTRA SPACE STORAGE INC COM							850
		FEDERAL RLTY INVT TR COM USD0.01							260
		GAMING & LEISURE PPTYS INC COM							374
		HEALTHCARE REALTY TRUST INC							173
		HEALTHPEAK OP LLC							346
		HIGHWOODS PPTYS INC COM							84
		HOST HOTELS & RESORTS INC REIT							376
		INVITATION HOMES INC COM							527
		IRON MTN INC NEW COM							754
		KILROY RLTY CORP COM							134
		KIMCO REALTY CORPORATION							416
		LINEAGE INC COM							78
		MEDICAL PPTYS TR INC COM REIT							77
		MID-AMER APT CMNTYS INC COM							500
		MILLROSE PROPERTIES INC. COM							141
		NATIONAL STORAGE AFFILIATES TR COM SHS							62
		NNN REIT INC							231
		OMEGA HEALTHCARE INVS INC REIT							406
		PARK HOTELS & RESORTS INC COM							62
		RAYONIER INC REIT							106
		REALTY INCOME CORP COM							1,601
		REGENCY CTRS CORP COM							385
		REXFORD INDL RLTY INC COM							280
		RITHM CAPITAL CORP							190
		SBA COMMUNICATIONS CORP							644
		SIMON PROPERTY GROUP INC COM							1,441
		STAG INDL INC COM							212
		STARWOOD PROPERTY TRUST INC COM REIT							196
		SUN COMMUNITIES INC COM							393
		UDR INC COM STK							355
		VENTAS INC REIT							1,121
		VICI PPTYS INC COM							934
		VORNADO RLTY TR COM							182
		W P CAREY INC COM							434
		WEYERHAEUSER CO COM							530
		Total REITs							23,846

		Collective trust funds
		BLACKROCK INTERNATIONAL MULTI CAP EQUITY FUND							116,749
		CAPITAL GROUP EUPAC TRUST							442,716
		CAPITAL GROUP GROWTH FUND OF AMERICA TRUST							1,506,310
		CAPITAL GROUP WASHINGTON MUTUAL INVESTORS TRUST							441,434

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Collective trust funds - continued
		GW&K SMALL-MID CAP CORE EQUITY FUND							159,818
*		NORTHERN TRUST COLLECTIVE MSCI ACWI EX-US INDEX FUND							229,531
*		NORTHERN TRUST COLLECTIVE SHORT TERM INVESTMENT FUND							17,255
		PIMCO TOTAL RETURN							229,481
		SSGA RUSSELL SMALL/MID CAP INDEX							910,059
		SSGA S&P 500 INDEX							2,622,633
		SSGA US BOND INDEX							186,789
		SSGA TARGET RETIREMENT 2025							416,322
		SSGA TARGET RETIREMENT 2030							654,000
		SSGA TARGET RETIREMENT 2035							681,640
		SSGA TARGET RETIREMENT 2040							598,322
		SSGA TARGET RETIREMENT 2045							536,656
		SSGA TARGET RETIREMENT 2050							455,296
		SSGA TARGET RETIREMENT 2055							317,868
		SSGA TARGET RETIREMENT 2060							189,986
		SSGA TARGET RETIREMENT 2065							68,655
		SSGA TARGET RETIREMENT 2070							5,058
		SSGA TARGET RETIREMENT INCOME							334,095
		Total Collective trust funds							11,120,673

		Futures contracts
		FUT MAR 26 IMMEMINI MDCP							997,560
		FUT MAR 26 IMMEMINI MDCP							(997,560)
		Total Futures contracts							—

		Corporate debt
		AMERICAN HONDA FIN CORP MED TERM NTS BOOVAR RT DUE 03-08-2027							5,112
		AMERICAN TOWER CORP NEW 1.6% DUE 04-15-2026 BEO							2,796
		AMERN HONDA FIN FLTG RT 4.400447% DUE 08-13-2027							2,004
		AMERN TOWER CORP 4.4% DUE 02-15-2026							253
		AVOLON HLDGS FDG 2.125% DUE 02-21-2026							240
		B A T INTL FIN PLC FIXED 1.668% DUE 03-25-2026							398
		BAIN CAP CR CLO FLTG RT 0% DUE 04-23-2035							999
		BANK OF AMERICA CORP 1.734% 07-22-2027							2,468
		BARCLAYS PLC 4.375% DUE 01-12-2026							4,800
		BARCLAYS PLC FLTG 09-13-2027							2,018
		BERRY GLOBAL INC 1.57% DUE 01-15-2026							1,898
		BOEING CO 2.25% DUE 06-15-2026							396
		BOEING CO FIXED 2.196% DUE 02-04-2026							9,183
		CANYON CLO 2021-4 FLTG RT 5.10331% DUE 10-15-2034							1,999
		CARMAX AUTO OWNER FLTG RT 4.34819% DUE 07-17-2028							5,173
		CARMAX AUTO OWNER TRUST SER 22-4 CL A3 5.34% DUE 08-16-2027 REG							602
		CGI INC 1.45% 09-14-2026							3,189
		CHASE AUTO OWNER TR 2024-5 NT CL A-2 144A 4.4% 11-26-2027							260
		CROWN CASTLE INTL 3.7% DUE 06-15-2026							4,989
		DELL INTL L L C/EMC CORP 4.9% 10-01-2026							1,105
		DLLAD 2024-1 LLC 5.5% DUE 08-20-2027							757
		ELEVATION CLO FLTG RT 0% DUE 07-25-2034							1,499
		ELLINGTON FINL MTG TR 2022-1 MTG PASS THRU CTF CL A-1 2.206% 01-25-2067							1,846
		EMERA US FIN LP 3.55% DUE 06-15-2026							299
		EXPORT DEV CDA FLTG RT 08-01-2028							3,006
		FORD CR AUTO LEASE TR 2024-B SR 24-B CL A2B FLTG RT 02-15-2027							337
		FORD CR AUTO OWNER 5.4% DUE 04-15-2027							743
		FORD MOTOR CREDIT CO LLC 5.8% 03-05-2027							2,835
		FORD MTR CR CO LLC 5.125% 11-05-2026							2,916
		GM FINL AUTOMOBILE LEASING TR SR 25-1 A2B FLTG RT 05-20-2027							290
		GOLDMAN SACHS BANK USA FLTG RT 03-18-2027							2,903
		GOLDMAN SACHS GROUP INC DUE 03-09-2027/03-09-2026 REG							1,401
		GS MTG BACKED SECS 4.54728% DUE 01-25-2052							2,159

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Corporate debt - continued
		HCA INC 5.25% DUE 06-15-2026							1,201
		HCA INC 5.375% DUE 09-01-2026							1,002
		HYUNDAI AUTO LEASE FLTG RT 4.04819% DUE 01-18-2028							2,500
		HYUNDAI CAP AMER VAR RT 4.727649% DUE 03-19-2027							2,639
		HYUNDAI CAP AMER VAR RT 5.164638% DUE 01-08-2027							1,381
		LLOYDS BANKING GROUP PLC 5.985% 08-07-2027							3,337
		MERCEDES-BENZ AUTO LEASE TRUST SR 24-B CL A2B FLTG RT 12-15-2026							394
		MFA 2020-NQM2 TR 1.381% DUE 04-25-2065							160
		MORGAN STANLEY 5.05% DUE 01-28-2027							3,002
		MORGAN STANLEY BANK FRN 10-15-2027							6,012
		NATWEST GROUP PLC 5.847% DUE 03-02-2027							2,005
		NAVESINK CLO 2 LTD / NAVESINK CLO 2 4.86219% 01-15-2036							900
		NAVIENT PRIVATE ED LN TR 2020-I 4.77413%04-15-2069							921
		NOMURA HOLDINGS INC 5.709% 01-09-2026							4,801
		OBX 2022-NQM1 TR MTG BACKED NT CL A-1 144A 2.305% 11-25-2061							1,698
		OBX 2022-NQM2 TR 2.783% DUE 01-25-2062							552
		ONEOK INC 4.25% 09-24-2027							1,204
		PAC GAS & ELEC CO FIXED 2.95% DUE 03-01-2026							2,988
		PAC GAS & ELEC CO FIXED 3.15% DUE 01-01-2026							942
		PNC BANK NA FLTG 01-15-2027							3,404
		PVTPL AGL CLO 14 LTD SR 21-14A CL AR FRN 12-02-2034							1,700
		PVTPL APIDOS CLO LTD SR 12-11A CL AR4 FRN 04-17-2034							1,300
		PVTPL APIDOS CLO XXXV LLC SER 21-35A CL A FLTG RT DUE 04-20-2034							250
		PVTPL ARES XXVII CLO LTD SR 13 2A CL A-R3 FLTG 10-28-2034							2,001
		PVTPL ARI FLEET LEASE TR 2023-A 5.41% 02-17-2032							162
		PVTPL ATHENE GLOBAL FUNDING FLTG 09-18-2028							697
		PVTPL ATHENE GLOBAL FUNDING FLTG RT 07-16-2026							8,212
		PVTPL ATHENE GLOBAL FUNDING FLTG RT 01-07-2027							2,004
		PVTPL ATLANTIC AVE 2024-3 LTD SR 24-3A CL A FLTG 01-20-2035							2,000
		PVTPL AVIATION CAPITAL GROUP 1.95% DUE 09-20-2026 BEO							3,345
		PVTPL BAIN CAPITAL CREDIT CLO LIMITED SR 20-2A CL ARR FLTG RT 07-19-2034							3,101
		PVTPL BAIN CAPITAL CREDIT CLO LTD SR 21-3A AR FLTG RT 07-24-2034							250
		PVTPL BANQUE FED CRED MUTUEL FLTG RT 01-23-2027							1,408
		PVTPL BLUEMOUNTAIN CLO LTD SR 22-34A CL AR FLTG RT 04-20-2035							300
		PVTPL BMW US CAP LLC FLTG 08-11-2027							2,005
		PVTPL BMW US CAPITAL LLC FLTG RT 144A 03-19-2027							402
		PVTPL CITIZENS AUTO RECEIVABLES TR TR 2024-2 SER 24-2 CL A3 5.33% 08-15-2028							333
		PVTPL CMO COLT 2021-4 MTG LN TR MTG PASSTHRU CTF CL A-1 10-25-2066							1,590
		PVTPL CQS US CLO LTD SER 21-1A CL AR FLTG 01-20-2035							2,002
		PVTPL CREDIT AGRICOLE S A LONDON BRH 1.247% 01-26-2027							998
		PVTPL GPMT 2021-FL3 LTD/GPMT 2021-FL3 LLC SR SECD NT CL A FLTG 07-16-2035							132
		PVTPL GUGGENHEIM CLO LTD SR 22-2A CL A1R FLTG RT 01-15-2035							1,000
		PVTPL JACKSON NATL LIFE GLOBAL 4.9% 01-13-2027							1,210
		PVTPL KKR FINANCIAL CLO LTD SR 42A CL ARFLTG RT 07-20-2034							2,000
		PVTPL KOMMUNALBANKEN AS FLTG RT 06-25-2027							8,006
		PVTPL LCM 31 LTD SR SECD NT CL A-R FLTG 07-20-2034							1,101
		PVTPL MADISON PK FDG SER 21-49A CL AR FLTG 10-19-2034							998
		PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE CO SER 21-FL7 CL A FLTG RT DUE 10-18-2036							1,000
		PVTPL NAVIENT PRIVATE ED REFI LN TR 2021-G CL A 1.58% DUE 04-15-2070 BEO							1,083
		PVTPL NAVIENT PRIVATE ED REFI LN TR SRS 20-HA CL A 1.31% DUE 01-15-2069							445
		PVTPL NAVIENT STUDENT LN TR 2014-1 SR 22-A CL A 2.23% 07-15-2070							824
		PVTPL NELNET STUDENT LN TR FLTG RT SER 19-2A CL A 06-27-2067 BEO							959
		PVTPL NISSAN MTR ACCEP CO LLC NT 1.85% 09-16-2026							878
		PVTPL NTT FIN CORP 03/04/2026 1.162% DUE04-03-2026/03-03-2021 BEO							3,970
		PVTPL OCEAN TRAILS CLO SR 21-11A CL AR FRN 07-20-2034							1,098
		PVTPL OCTAGON LTD SR 22-1A CL A1R FLTG RT 07-21-2035							2,200

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Corporate debt - continued
		PVTPL PARALLEL LTD SR 21-1A CL AR FLTG RT 07-15-2034							2,598
		PVTPL POST CLO LTD 21-1A AR FLTG RATE DUE 10-15-2034 BEO							1,999
		PVTPL REGATTA XVI FUNDING LTD SR 19-2A CL A1R FLTG RT 01-15-2033							3,375
		PVTPL RELIANCE STD LIFE GLOBAL FDG II 1.512% 09-28-2026							5,137
		PVTPL RGA GLOBAL FDG 2.0% 11-30-2026							491
		PVTPL ROCKFORD TOWER CLO LTD SR22-1A CL A1R VAR RT 07-20-2035							500
		PVTPL ROMARK CLO LTD 2021-4 SR 21-4A CL A1R FLTG 07-10-2034							2,000
		PVTPL SBA TOWER TR 4.831% 10-15-2029							1,410
		PVTPL SHACKLETON CLO LTD SR 19-14A CL A1R FLTG RT 07-20-2034							1,701
		PVTPL SILVER ROCK CLO LTD 2021-2 SR 21-2A L AR FTG RT 01-20-2035							999
		PVTPL SYMPHONY CLO LTD SR 20-22A CL A1ARFLTG RT 04-18-2033							839
		PVTPL SYMPHONY CLO LTD SR 21-25A CL AR FLTG RT 04-19-2034							500
		PVTPL THAYER PK CLO LTD SER 17-1A CL A1RR FLTG 04-20-2034							1,298
		PVTPL TOWD POINT MORTGAGE TRUST SER 21-1 CL A1 VAR 11-25-2061							1,236
		PVTPL TOYOTA LEASE OWNER TRUST SR 24-B CL A2B FLTG RT 02-22-2027							182
		PVTPL TRINITAS CLO LTD SER 17-7A CL A1R2 FLTG RT 01-25-2035							999
		PVTPL TTRALEE CLO LTD SER 18-5A CL A1RR FLTG 10-20-2034							899
		PVTPL UBS GROUP AG 1.305% 02-02-2027							6,879
		PVTPL UNITED OVERSEAS BANK LTD FLTG 04-02-2028							3,707
		PVTPL USAA AUTO OWNER TRUST SER 23-A CL A3 5.58% DUE 05-15-2028							436
		PVTPL VICI PROPERTIES INC 4.5% 09-01-2026							1,001
		PVTPL VOLKSWAGEN GROUP AMER FIN LLC 5.7% 09-12-2026							404
		PVTPL VOYA CLO LTD SR 19-2A CL AR FLTG 07-20-2032							831
		PVTPL WHETSTONE PK CLO LTD/WHETSTONE PK CLO SR 21-1A CLS A1R FLTG 01-20-2035							1,499
		PVTPL WIND RIV 2021-2 CLO LTD/WIND RIV 2021- SR 21-2A CL A1R VAR RT 07-20-2034							1,200
		ROCKFORD TOWER CLO FLTG RT 5.32886% DUE 07-20-2034							4,098
		SARANAC CLO VI LTD / SARANAC CLO VI 5.12481% 08-13-2031							199
		SOFI PROFESSIONAL LN PROGRAM 2020-C POSTGRADUATE LN AST BKD NT 1.95% 02-15-2046							623
		SOUTHERN CALIF EDISON CO 4.9% 06-01-2026							4,106
		VOLKSWAGEN GROUP AMER FIN LLC FLTG 03-20-2026							3,303
		WORLD OMNI FLTG RT 4.13735% DUE 02-16-2027							133
		Total Corporate debt							227,462

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity
				date &
				range of				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		interest		(d) Cost ^**		value
		Government debt
		FANNIE MAE SR 24-103 CL FC FLTG RT 01-25-2055							816
		FANNIE MAE SR 24-90 CL FB FLTG RT 11-25-2053							2,320
		FANNIE MAE SR 25-18 CL FM FLTG RT 09-25-2054							973
		FANNIE MAE SR 25-95 CL F FLTG RT 12-25-2053							1,574
		FANNIE MAE TR SR 24-95 CL KF FLTG 12-25-2054							1,213
		FEDERAL HOME LN MTG CORP SER 005557 CL FM 4.76721% 07-25-2055							1,369
		FEDERAL HOME LN MTG CORP SER 005584 CL DF 4.56721% 10-25-2055							483
		FEDERAL HOME LN MTG CORP SER 5442 CL FB FLTG 08-25-2054							2,114
		FEDERAL HOME LN MTG CORP SER 5565 CL FA FLTG RT 08-25-2055							1,139
		FEDERAL HOME LN MTG CORP SER 5567 CL FB FLTG RT 08-25-2055							180
		FEDERAL HOME LN MTG CORP SR 5560 CL FB FLTG RT 06-25-2055							1,246
		FEDERAL HOME LN MTG CORP SR 5601 CL F FLTG RT 11-25-2055							496
		FEDERAL NATIONAL MORTGAGE ASSOC REMIC TR2024-100 CL-FA VAR 4.76721% 06-25-2054							1,363
		FHLMC SR 5480 CL FG FLTG RT 12-25-2054							681
		FHLMC SR 5565 CL FB FLTG 08-25-2055							988
		FNMA FLTG RT 11-05-2027							6,010
		FNMA REMIC TR 2024-101 CL-FB VAR 4.76721% 01-25-2055							1,756
		FNMA REMIC TR 2024-104 CL-FA VAR 4.71721% 01-25-2055							820
		FNMA REMIC TR 2025-35 CL-FB VAR 4.66721%05-25-2055							583
		FNMA SR 25-35 CL FM FLTG RT 05-25-2055							377
		FNMA SR 25-54 CL FM FLTG RT 07-25-2055							824
		FREDDIE MAC MULTICLASS SR 5410 CL FB FLTG RT 05-25-2054							1,233
		FREDDIE MAC SER 5508 CL DF FLTG RT 02-25-2055							1,475
		FREDDIE MAC SER 5508 CL FC FLTG 02-25-2055							746
		FREDDIE MAC SR -5544 CL F FLTG RT 06-25-2055							1,340
		FREDDIE MAC SR 5484 CL FA FLTG RT 12-25-2054							1,455
		FREDDIE MAC SR 5493 CL FK FLTG 01-25-2055							788
		FREDDIE MAC SR 5500 CL UF FLTG 11-25-2054							1,294
		FREDDIE MAC SR 5508 CL AF FLTG RT 02-25-2055							2,466
		FREDDIE MAC SR 5513 CL MF FLTG RT 11-25-2054							3,013
		GNMA 2016-H17 MTG PASS THRU CTF CL MX FC08-20-2066							159
		GNMA 2016-H20 REMIC PASSTHRU CTF CL MX-PT 09-20-2066							371
		GNMA REMIC PASSTHRU SER 2016-H11 CLS F 05-20-2066							29
		GNMA SR 23-H22 CL FB FLTG RT 09-20-2073							2,858
		GNMA SR 25-98 CL GF FLTG RT 06-20-2055							885
		GNMA SR 25-H20 CL FA FLTG RT 09-20-2075							251
		GNMA SR 25-H22 CL F FLTG RT 10-20-2075							250
		UNITED STATES TREASURY BILLS 0% 05-07-2026							70
		UNITED STATES OF AMER TREAS NOTES 4.0% 02-28-2030							58,275
		UNITED STATES TREAS NTS DTD 04/30/2025 3.875% 04-30-2030							3,833
		UNITED STATES TREAS NTS DTD 07/31/2025 3.875% 07-31-2030							76,223
		Total Government debt							184,339

		Private 40-Act mutual funds
		PIMCO SHORT-TERM FLOATING NAV PORTFOLIO II							398,213

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity date &				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		range of interest		(d) Cost ^**		value
				Interest rates 3.25% to 9.75%
*		Loans to participants		Various maturities through 2047					107,491
								$	17,767,239

*	Represents a party-in-interest transaction.

**	Cost information omitted as all investments are fully participant directed.

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ABBOTT LABORATORIES STOCK RETIREMENT PLAN (PUERTO RICO)

DECEMBER 31, 2025 and 2024

C O N T E N T S

	Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	3

FINANCIAL STATEMENTS

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS	4

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS	5

NOTES TO FINANCIAL STATEMENTS	6

SUPPLEMENTAL SCHEDULE

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)	13

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) as of December 31, 2025 and 2024, the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2025 and 2024, and the changes in net assets available for benefits for the year ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

Supplemental information

/s/ GRANT THORNTON LLP

We have served as the Plan’s auditor since 2014.

Chicago, Illinois

June 18, 2026

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS

December 31, 2025 and 2024

(Dollars in thousands)


		2025			2024
Assets
Cash		$	30		$	27
Investments, at fair value			264,892			237,222
Notes receivable from participants			6,124			5,803
Due from brokers			6			22
Accrued interest income			40			225

NET ASSETS AVAILABLE FOR BENEFITS		$	271,092		$	243,299

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

Year ended December 31, 2025

(Dollars in thousands)


Additions
Contributions
Employer	$	2,527
Participant		5,179
Rollovers		110

Total contributions		7,816

Investment income
Net appreciation in fair value of investments		34,461
Interest and dividends		6,246

Net investment income		40,707

Interest income on notes receivable from participants		429

Net additions		48,952

Deductions
Benefits paid to participants		21,133
Other expenses		26

Total deductions		21,159

NET INCREASE		27,793

Net assets available for benefits
Beginning of year		243,299

End of year	$	271,092

The accompanying notes are an integral part of this statement.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS

December 31, 2025 and 2024

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan was established January 1, 2013 in conjunction with Abbott Laboratories (“Abbott”) separating into two publicly traded companies – Abbott and AbbVie Inc. (“AbbVie”). The Plan covers employees of Abbott’s selected subsidiaries and affiliates in Puerto Rico (the “Company”).

The Plan is a profit-sharing plan containing a cash or deferred arrangement intended to qualify for favorable tax treatment under sections 1081.01 (a) and (d) of the Puerto Rico Internal Revenue Code of 2011, as amended. In addition, the Plan provides an arrangement by which employees may invest in Abbott shares. Employees of the Company may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

The Plan’s sponsor is Abbott Healthcare (Puerto Rico) S.a.r.l. Alight Solutions serves as the recordkeeper of the Plan. The Northern Trust Company (“Custodian”) and Banco Popular de Puerto Rico (“Trustee”) serve as the Plan’s custodian and trustee, respectively. The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

Contributions and Vesting

Contributions to the Plan are paid to a trust administered by the Trustee. An investment committee (the “Committee”) may direct the Trustee to establish investment options of the Committee’s choosing.

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate may contribute from 2% (or 1%, for Abbott Green participants) to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from either pretax earnings or after-tax earnings, or both. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contribution are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options, except for investment options closed to new contributions.

Employer matching contributions to the Plan are made each payroll period based on the participating employees’ eligible earnings. Excluding the Abbott Green participants, the employer contribution for the year ended December 31, 2025 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan. Effective with the first pay period ending after March 1, 2017, employer matching contributions for Abbott Green participants are made at the rate of 100% up to a 3% deferral of eligible earnings. Employer contributions are invested each pay period according to the participant’s investment elections.

In connection with the January 1, 2013 separation of Abbott into two publicly traded companies, Abbott shareholders received as a tax-free distribution one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Plan participants may continue to hold the AbbVie stock they received from the distribution; however, they may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan. AbbVie dividends are invested in the Plan’s default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other investment options available to the participants.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:


		Vesting
Service		percentage
Less than two years		0%
Two years or more		100%

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65.

Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in matching contributions upon qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Through December 31, 2024, forfeitures were used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, (2) pay Plan expenses as deemed appropriate by the administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. Effective January 1, 2025, forfeitures are used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, and (2) reduce future employer contributions if terminated participants do not return to service within the given period of time.

In 2025, approximately $35,600 of forfeitures were used to reduce employer contributions. Forfeitures totaling approximately $107,900 and $109,300 were available at the end of 2025 and 2024, respectively.

Distributions and In-Service Withdrawals

Following retirement, termination or death, participants or their beneficiaries may elect to receive a distribution in installments, a single lump sum or a partial lump sum. Participants may elect a direct rollover of their accounts. Interest, dividends and other earnings will continue to accrue on any deferred amounts prior to distribution.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, are subject to certain limitations.

Notes Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to Puerto Rico Internal Revenue Code limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years. Repayment is generally made through periodic payroll deductions or by sending in a payment, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

Investment Valuation

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock and mutual funds - Valued at the published market price per share or unit multiplied by the number of shares or units held.

Collective trust funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

The following tables summarize the basis used to measure investments at fair value at December 31, 2025 and 2024 (dollars in thousands):


		Basis of Fair Value Measurement
		Quoted			Significant
		Prices in			Other			Significant
		Active			Observable			Unobservable			Measured at
2025		Markets			Inputs			Inputs			NAV			Total
Common stock		$	106,951		$	—		$	—		$	—		$	106,951
Mutual funds			52,452			—			—			—			52,452
Collective trust funds			—			—			—			105,489			105,489
Total investments, at fair value		$	159,403		$	—		$	—		$	105,489		$	264,892


		Basis of Fair Value Measurement
		Quoted			Significant
		Prices in			Other			Significant
		Active			Observable			Unobservable			Measured at
2024		Markets			Inputs			Inputs			NAV			Total
Common stock		$	96,512		$	—		$	—		$	—		$	96,512
Mutual funds			48,681			—			—			—			48,681
Collective trust funds			—			—			—			92,029			92,029
Total investments, at fair value		$	145,193		$	—		$	—		$	92,029		$	237,222

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation – Continued


	2025
	Fair value			Redemption		Redemption
	(NAV)			frequency		notice period		Restrictions
Funds filing as direct filing entity:
Collective trusts	$	105,489		Daily		0 - 5 days		—


		2024
		Fair value			Redemption		Redemption
		(NAV)			frequency		notice period		Restrictions
Funds filing as direct filing entity:
Collective trusts		$	92,029		Daily		0 - 5 days		—

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Contributions

Contributions from Plan participants and the matching contributions from the employer are recorded in the year in which the employee contributions are withheld from compensation.

Administrative Expenses

Participants are charged transaction fees for loan processing, which are included in other expenses and commissions on purchases and sales of Abbott shares and sales of AbbVie shares, which are included in net appreciation in fair value of investments. Investment fees for mutual funds and collective trusts are charged against the net assets of the respective fund and are also included in net appreciation in fair value of investments. The Company pays other recordkeeping and administration fees, where applicable. Expenses paid by the Company are excluded from these financial statements.

Payment of Benefits

Benefits are recorded when paid.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2025 and 2024 is presented below:


	2025			2024
Abbott common shares, 529,424 and 553,452 shares, respectively (dollars in thousands)	$	66,331		$	62,601
Market price per share	$	125.29		$	113.11

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Custodian. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2025, the Plan received $1,282,300 in common stock dividends from Abbott.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

NOTE F - TAX STATUS

The Plan received letters dated April 19, 2016 and December 2, 2019 from the Department of the Treasury of the Commonwealth of Puerto Rico that the Plan, as written, qualifies under Section 1081.01(a) of the Puerto Rico Internal Revenue Code of 2011, as amended and, consequently, its enabling trust is exempt from local income tax. The Plan has been amended since receiving the letters. The Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable Puerto Rico Internal Revenue Code.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2025 and 2024, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress.

NOTE G - RISKS AND UNCERTAINTIES

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2025 and 2024

NOTE H – SUBSEQUENT EVENTS

The following changes took effect on January 1, 2026:

A participant who has a balance in the AbbVie common stock investment option will have dividends invested across the participant’s investment elections on file for future contributions.

SUPPLEMENTAL SCHEDULE

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

EIN: 98-1051267, Plan Number: 002

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

December 31, 2025

(Dollars in thousands)


				(c) Description
				of investment
				including
				maturity date &				(e) Current
(a)		(b) Identity of issue, borrower, lessor, or similar party		range of interest		(d) Cost ^**		value
		Common stock - employer securities
*		Abbott Laboratories, common shares						$	66,331

		Common stock
		AbbVie Inc., common stock							40,620
		Total Common stock							106,951

		Mutual funds
		American Funds EUPAC Fund							7,435
		American Funds The Growth Fund of America Fund							21,768
		American Funds Washington Mutual Investors Fund							5,489
		PIMCO All Asset Fund							2,106
		PIMCO Short Asset Investment Fund							12,015
		Vanguard Mid-Cap Value Index Fund Admiral							3,639
		Total Mutual funds							52,452

		Collective trust funds
		Blackrock International Opportunities Fund							2,079
		GW&K Small-Mid Cap Core Equity Fund							3,112
*		Northern Trust Collective ACWI ex-U.S. Index Fund							2,086
*		Northern Trust Collective Short Term Investment Fund							108
		PIMCO Total Return Fund							1,993
		SSGA Russell Small/Mid Cap Index Fund							4,327
		SSGA S&P 500 Index Fund							22,624
		SSGA U.S. Bond Index Fund							1,698
		SSGA Target Retirement 2025							9,990
		SSGA Target Retirement 2030							12,500
		SSGA Target Retirement 2035							9,338
		SSGA Target Retirement 2040							9,485
		SSGA Target Retirement 2045							7,371
		SSGA Target Retirement 2050							4,796
		SSGA Target Retirement 2055							2,980
		SSGA Target Retirement 2060							1,164
		SSGA Target Retirement 2065							529
		SSGA Target Retirement 2070							2
		SSGA Target Retirement Income							9,307
		Total Collective trust funds							105,489
				Interest rates 3.25% to 8.50%
*		Loans to participants		Various maturities through 2040					6,124
								$	271,016

^*	Represents a party-in-interest transaction.

^**	Cost information omitted as all investments are fully participant directed.

EXHIBIT INDEX

Exhibit No.		Exhibit
23.1		Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan.

23.2		Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan (Puerto Rico).

SIGNATURE

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM